|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Rhesus DPP4 ORF mammalian expression plasmid, C-GFPSpark tag||CG90180-ACG|
|Rhesus DPP4 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||CG90180-ACR|
|Rhesus DPP4 ORF mammalian expression plasmid, C-Flag tag||CG90180-CF|
|Rhesus DPP4 ORF mammalian expression plasmid, C-His tag||CG90180-CH|
|Rhesus DPP4 ORF mammalian expression plasmid, C-Myc tag||CG90180-CM|
|Rhesus DPP4 ORF mammalian expression plasmid, C-HA tag||CG90180-CY|
|Rhesus DPP4 Gene cDNA clone plasmid||CG90180-G|
|Rhesus DPP4 ORF mammalian expression plasmid, N-Flag tag||CG90180-NF|
|Rhesus DPP4 ORF mammalian expression plasmid, N-His tag||CG90180-NH|
|Rhesus DPP4 ORF mammalian expression plasmid, N-Myc tag||CG90180-NM|
|Rhesus DPP4 ORF mammalian expression plasmid, N-HA tag||CG90180-NY|
|Rhesus DPP4 natural ORF mammalian expression plasmid||CG90180-UT|
|Learn more about expression Vectors|
Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.